Clinical Utility of Pre-Treatment and Surveillance Circulating Tumor Tissue Modified Viral HPV DNA to Detect Recurrence in a Community Based HN Cancer Program

O. Russial,A. Raben,S. Shah,N. Hockstein,S. Park,L. Clements,J. Cormier

DOI: https://doi.org/10.1016/j.ijrobp.2024.01.166

IF: 8.013

2024-04-01

International Journal of Radiation Oncology*Biology*Physics

Abstract:Purpose/Objective(s) Circulating tumor tissue modified viral (TTMV)-HPV DNA is a tool to aid in the diagnosis and surveillance of patients with HPV-positive oropharyngeal squamous cell carcinoma (OPSCC). Our site was one of the early adopters of the use of TTMV-HPV DNA in a community-based hospital setting, with most of our patients receiving pre- and post-treatment testing. Materials/Methods A total of 401 TTMV-HPV DNA assays (liquid biopsies) were prospectively collected on 115 Pts with OPSCC between 2020 and 2023. Initial HPV status was assessed by p16 marker and then by TTMV-HPV DNA assay. Test results were correlated with imaging to assess clinical utility. Results The median age of this cohort was 65 years (range: 27-83) with most pts having involved nodes at initial diagnosis (92%). In contrast to other studies, a relatively high proportion of Pts in this cohort were female (21%). All Pts were treated with curative-intent with surgery and risk adaptive adjuvant/neoadjuvant therapies or with definitive chemo-radiation alone. 43% received standard chemo-radiation course, and six patients (5%) received de-escalated dose via the DART regimen. Median follow-up was 14.8 months. The majority of pts had pretreatment testing (87%) with median TTMV of 757 (range: 7 - 407,471). The scores of males and females were not statistically significantly different (t-test of log10-transformed scores, p=0.9). The pretreatment sensitivity of the p16-positive cohort was 88.2% (95% CI: 80.9 - 95.4%). These results correlate well with the combined data of seven other studies published by large academic centers, which showed a sensitivity of 90.4% (95% CI: 87.4 - 93.4%). In pts with a positive pretreatment test, 93% had their score resolved to zero within 3 months after initial treatment and none exhibited clinical evidence of residual disease on imaging. Pts with N2-N3 disease were less likely to achieve test resolution than Pts with N0-N1 disease (Fisher's exact test, p = 0.0294). Surveillance tests were primarily collected every three months after treatment completion for the first two years and every six months thereafter with a median of 3 tests (range: 1-11). Currently, two Pts tested TTMV-HPV DNA positive without clinical detection of recurrence who were treated with the DART regimen. Both Pts are without radiographic recurrence and remain under active surveillance. Conclusion As one of the earliest community-based HN-MDC programs to adopt both Pre- and Post treatment TTMV-HPV DNA testing for HPV-OPSCC, our findings are in line with larger academic centers and support the clinical utility of TTMV-HPV DNA testing in the setting of a community-based practice. The higher percentage of women in our cohort is unusual. Furthermore, although there was no statistical significance comparing pre-treatment test sensitivity in female and male subgroups, there was a trend toward lower sensitivity in females and warrants further investigation in a larger cohort.

oncology,radiology, nuclear medicine & medical imaging